Arch Oncology

Arch Oncology is a biotechnology company founded in 2006 and based in the United States. The company is primarily focused on developing groundbreaking antibody therapies for the treatment of solid tumors and hematologic malignancies. Their lead product candidate AO-176 is currently in Phase 1/2 clinical trials for the treatment of select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies. One of the key differentiators of Arch Oncology's next-generation anti-CD47 antibodies, particularly AO-176, is its ability to block the "don’t eat me" signal for macrophages, inducing Immunogenic Cell Death in addition to directly killing tumor cells. Importantly, AO-176 binds preferentially to CD47 on tumor cells and displays increased efficacy in low pH conditions, such as the tumor microenvironment. Arch Oncology recently received a significant $105.00M Series C investment from a consortium of notable investors including 3x5 Partners, RiverVest, Adage Capital Management, Avego Bioscience Capital, Broadfin Capital, Cowen Digital, Lightchain, Roche Venture Fund, FMB Research, and Eventide, on 27th April 2021. The company's headquarters are located in Brisbane, CA, known for its status as a biotechnology innovation hub, with its scientific research laboratory based in St. Louis, MO, the home of the famous Gateway Arch.